The current invention provides peptide nucleic acid derivatives targeting a part of the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce splice variants of the SCN9A mRNA in cells, and are useful to safely treat pains or conditions involving Na
v
1.7 activity.
Lugowkin, Zhurnal Obshchei Khimii, 1956, vol. 26, p. 1733,1734; engl. Ausg. S. 1945